48.78
+2.4(+5.17%)
Currency In USD
Address
99 High Street
Boston, MA 02110
United States of America
Phone
617 300 8460
Sector
Healthcare
Industry
Biotechnology
Employees
116
First IPO Date
October 16, 2020
| Name | Title | Pay | Year Born |
| Mr. Marcio Silva De'Souza M.B.A. | President, Chief Executive Officer & Director | 1.64M | 1979 |
| Mr. Alex Nemiroff J.D. | General Counsel & Secretary | 816,300 | 1979 |
| Mr. Timothy Edwin Kelly | Chief Financial Officer & Treasurer | 943,077 | 1973 |
| Lauren Mastrocola | Vice President of Finance & Principal Accounting Officer | 0 | N/A |
| Ms. Megan T. Sniecinski | Chief Business Officer | 0 | 1982 |
| Ms. Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | 0 | 1975 |
| Dr. Steven Petrou B.Sc. (Hons.), Ph.D. | Co-Founder & Chief Scientific Officer | 0 | N/A |
| Mr. Alex Kane | Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Ms. Kelly McCue | Chief People Officer | 0 | N/A |
| Dr. Karl Hansen Ph.D. | Chief Technical Operations Officer | 0 | N/A |
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.